Gene Therapy in CNS Disorder Market

Future Market Insights

Key Insight

Gene therapy in CNS disorder sales will rise through 2036, driven by in vivo gene therapy at 63.5% of the gene type in 2026. The market was valued at USD 13.96 billion in 2025 and is expected to be worth USD 248.39 billion by 2036, creating an incremental opportunity of USD 230.38 billion.

May 26, 2026

Anurag Sharma

301 Pages

Cite this Report

Gene Therapy in CNS Disorder Market

https://www.futuremarketinsights.com/reports/gene-therapy-in-cns-disorder-market

License

Buy Now

Summary ToC Infographics Companies

Key Players

Biogen Inc
CRISPR Therapeutics AG
Neurocrine Biosciences
Novartis
The Vanguard Group
Samsung Biologics
Sangamo Therapeutics
Sarepta Therapeutics Inc
Shape Therapeutics
Spark Therapeutics (Roche)
UniQure
Vertex Pharmaceuticals Incorporated
Voyager Therapeutics

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Gene Therapy in CNS Disorder Market

Key Players

Similar Industry Reports